Why do hospitals outsource medical equipment management?

Managing medical equipment is complex — hospitals need thousands of devices maintained, calibrated, repaired, and tracked. Running an in-house biomedical engineering department requires specialized technicians, parts inventory, and management expertise. Outsourcing to Agiliti provides variable-cost access to equipment expertise, potentially better device availability, and frees hospital management focus for clinical priorities.

Which pharmaceutical companies license ENHANZE technology?

Halozyme's ENHANZE partners include Roche/Genentech (Herceptin SC, MabThera/Rituxan SC, Phesgo, Tecentriq), Janssen (Darzalex SC for multiple myeloma), AbbVie (Imbruvica SC), argenx (efgartigimod SC for myasthenia gravis), and several other pharma companies in various stages of clinical development or regulatory review for their ENHANZE-enabled drugs.

What is the patient benefit of subcutaneous versus intravenous drug administration?

IV infusions require patients to go to a clinic or infusion center, sit for 2-8 hours while drug infuses through an IV line, and may require monitoring — a major time and logistics burden, especially for chronic disease treatments requiring frequent dosing. SC injection takes minutes and can often be self-administered at home — dramatically improving quality of life and reducing healthcare system cost from clinic infusion visits.

Data as of: June 16, 2026

brimindinvest.com / compare / agiliti-vs-haloLIVE

AGTI

Agiliti, Inc. · Health Care - Medical Equipment Services

N/A

N/A this month

VERSUS

COMPARE

HALO

Halozyme Therapeutics, Inc. · Health Care - Biotechnology / Drug Delivery

N/A

N/A this month

Comparison scoreboard

MIXED SETUP

AI Scorei

AGTI N/A

HALO N/A

1Y Returni

AGTI N/A

HALO N/A

Fwd P/Ei

AGTI N/A

HALO N/A

Target Up.i

AGTI N/A

HALO N/A

Op. Margini

AGTI N/A

HALO N/A

Quick take

AGTI vs HALO Stock Comparison: AI Score, Valuation, Performance and Upside

ShareX LinkedIn Reddit Facebook WhatsApp

AGTI (Agiliti) provides hospital medical equipment management services in a B2B outsourcing model, while HALO (Halozyme) licenses its ENHANZE drug delivery technology to pharmaceutical companies earning royalties on each unit sold of drugs converted from IV to subcutaneous forms. These companies serve very different aspects of healthcare with different risk/return profiles.

AGTI vs HALO contrasts hospital equipment management outsourcing services against a pharmaceutical drug delivery technology royalty business — recurring service revenue versus asset-light royalty stream from pharmaceutical licensing.

Normalized 1Y performance

AGTI

HALO

Not enough data to chart yet.

Recent returns

AGTI

HALO

Not enough data to chart yet.

Analyst price targets & sentiment

Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.

AGTI

Price target data unavailable

N/A

HALO

Price target data unavailable

N/A

Who should consider this stock?

AGTI may suit investors who:

Want hospital equipment management service exposure leveraging the outsourcing trend in healthcare operations
Value Agiliti's recurring service contracts as predictable revenue versus volatile equipment capital purchases
See hospital operational efficiency pressure as a structural driver of outsourcing biomedical equipment management

HALO may suit investors who:

Want a pharmaceutical drug delivery royalty business earning compounding royalties as ENHANZE enables more IV-to-SC drug conversions
Value Halozyme's asset-light model — high-margin royalties from partner drug sales with no manufacturing risk
See the patient convenience and healthcare economics benefit of SC conversion as driving continued pharmaceutical partner adoption of ENHANZE

Performance & AI score

Performance & AI score
Metric	AGTI	HALO
AI scorei	N/A	N/A
AI ranki	N/A	N/A
Latest closei	N/A	N/A

Valuation & upside potential

Valuation & upside potential
Metric	AGTI	HALO
Market capi	N/A	N/A
Trailing P/Ei	N/A	N/A
Forward P/Ei	N/A	N/A
Price/Salesi	N/A	N/A
EV/Revenuei	N/A	N/A
Analyst targeti	N/A	N/A
Target upsidei	N/A	N/A

Growth, profitability & risk

Growth, profitability & risk
Metric	AGTI	HALO
Revenue growthi	N/A	N/A
Earnings growthi	N/A	N/A
EPS growthi	N/A	N/A
FCF margini	N/A	N/A
Operating margini	N/A	N/A
Profit margini	N/A	N/A
ROIC proxyi	N/A	N/A
Return on equityi	N/A	N/A
Dividend yieldi	N/A	N/A
Payout ratioi	N/A	N/A
Dividend growth streaki	N/A	N/A
Betai	N/A	N/A
Debt/equityi	N/A	N/A
Current ratioi	N/A	N/A
Quick ratioi	N/A	N/A

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

AGTI max drawdowniN/A

HALO max drawdowniN/A

AGTI max wkly dropiN/A

HALO max wkly dropiN/A

5Y risk snapshot

AGTI max drawdowniN/A

HALO max drawdowniN/A

AGTI max wkly dropiN/A

HALO max wkly dropiN/A

10Y risk snapshot

AGTI max drawdowniN/A

HALO max drawdowniN/A

AGTI max wkly dropiN/A

HALO max wkly dropiN/A

Performance metrics by period

Performance metrics by period
Period	Metric	AGTI	HALO
1Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
5Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
10Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A

AI Prediction Signali

Members only

Next 5 trading days

AGTI

+2.8%BUY

HALO

+1.1%HOLD

Next 30 trading days

AGTI

+6.4%BUY

HALO

+3.2%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Business comparison

Business comparison
Category	AGTI	HALO
Company	Agiliti, Inc.	Halozyme Therapeutics, Inc.
Sector	Health Care - Medical Equipment Services	Health Care - Biotechnology / Drug Delivery
Industry	N/A	N/A
Core business	Agiliti provides outsourced medical equipment management and repair services to hospitals and health systems — managing, repairing, and maintaining medical devices like infusion pumps, patient monitoring equipment, and surgical instruments, allowing hospitals to focus on clinical care.	Halozyme's ENHANZE drug delivery technology uses the enzyme HYALURONIDASE (rHuPH20) to break down hyaluronan in subcutaneous tissue, enabling large-volume drug injections under the skin that would normally require intravenous (IV) infusion — converting IV drugs to more convenient subcutaneous (SC) forms.
Investor focus	Investors track Agiliti's hospital partnership revenue, medical equipment utilization rates, and the outsourcing trend as hospitals seek to reduce capital equipment spend and operational complexity in their biomedical engineering departments.	Investors track ENHANZE royalty revenues from pharmaceutical partners (Roche, Janssen, AbbVie, argenx, and others), the number of approved drugs using ENHANZE technology, and the pipeline of drugs converting from IV to SC using ENHANZE.

AGTI strengths

Hospitals increasingly outsource medical equipment management as capital constraints and focus on core clinical care drive interest in equipment-as-a-service models
Agiliti's scale of equipment management and repair creates network effects — managing equipment across many hospitals improves parts availability and technician expertise
Recurring service and equipment utilization revenue provides more predictable income than one-time capital equipment sales

HALO strengths

ENHANZE technology converts IV biologic drugs to more convenient SC injection — dramatically improving patient experience and enabling at-home administration versus clinic IV infusions
Asset-light royalty model — pharmaceutical partners pay royalties for each unit sold of ENHANZE-enabled drugs, with minimal manufacturing cost for Halozyme
Growing portfolio of approved ENHANZE partnerships generates compounding royalty revenue as more drugs adopt the technology

Risks to watch — AGTI

Hospital capital spending cycles affect Agiliti — tight hospital budgets can delay outsourcing decisions or reduce rental utilization
Labor costs for biomedical equipment technicians are rising, potentially compressing service margins
Competition from hospital in-house biomedical departments and other equipment service companies

Risks to watch — HALO

ENHANZE royalty stream depends on continued strong sales of partner drugs — if a key partner drug loses market share or faces competition, Halozyme's royalties decline
Not all drugs are suitable for ENHANZE conversion — the addressable market requires IV biologics with the right characteristics for subcutaneous delivery
As patents on core ENHANZE technology eventually expire, competition from generic hyaluronidase products could commoditize the technology

Frequently asked questions

ENHANZE uses rHuPH20 (an enzyme that temporarily breaks down hyaluronan in the skin) to create a larger space in subcutaneous tissue, allowing larger volumes of drug solution to be injected under the skin. This converts drugs previously given via IV infusion (requiring clinic visits, nursing time, and IV access) to self-injectable SC forms — dramatically improving convenience, enabling at-home treatment, and reducing healthcare costs.

Interactive comparison engine

Compare more than two at a time

This page is a fixed writeup on AGTI and HALO. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.

Up to 5 tickers at once

Add three more names beside AGTI and HALO, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.

Scoreboard verdict

AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.

Full risk suite

Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.

Correlation heatmap

Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.

Valuation vs profitability

A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.

Holdings overlap and CSV export

For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.

Open AGTI vs HALO in the engine See what's included

Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

Related comparisons